January–June 2026 compared with January–June 2025 Net sales declined 6% to SEK 9,893m (10,541). The lower net sales were mainly driven by lower selling prices and negative exchange rate effects, which were offset by higher delivery volumes. EBITDA amounted to SEK 2,410m (3,684). The decrease was primarily attributable to lower selling prices, negative exchange rate effects and higher raw material costs.
BSN medical’s sales and EBITDA for 2016
- Regulatory press release
As SCA communicated in December 2016, the Group has entered into an agreement to acquire BSN medical, a leading medical solutions company. Closing is expected to take place during the second quarter 2017. BSN medical’s sales for 2016 amounted to EUR 850m (SEK 8,038m) and adjusted EBITDA1) for 2016 amounted to EUR 210m (SEK 1,986m).
1)Excluding items affecting comparability
NB: This information is information that SCA is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 20:00 CET on March 9, 2017.
Karl Stoltz, Media Relations Manager, +46 8 788 51 55
For additional information please contact:
Johan Karlsson, Vice President Investor Relations, 46 (0)8 788 51 30
Karl Stoltz, Media Relations Manager, 46 (0)8 788 51 55